TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.

doi:10.1200/JCO.2014.57.6660

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Jun 2015

Isakoff Steven J, Mayer Erica L, He Lei, Traina Tiffany A, Carey Lisa A, Krag Karen J, Rugo Hope S, Liu Minetta C, Stearns Vered, Come Steven E, Timms Kirsten M, Hartman Anne-Renee, Borger Darrel R, Finkelstein Dianne M, Garber Judy E, Ryan Paula D, Winer Eric P, Goss Paul E, Ellisen Leif W

Abstract excerpt

PURPOSE: The identification of patients with metastatic triple-negative breast cancer (mTNBC) who are expected to benefit from platinum-based chemotherapy is of interest. We conducted a single-arm phase II clinical trial of single-agent platinum for mTNBC with biomarker correlates. PATIENTS AND METHODS: Patients with mTNBC received first- or second-line cisplatin (75 mg/m(2)) or carboplatin (area under the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carboplatin

Share to Cisplatin

Share to Class I Phosphatidylinositol 3-Kinases

Share to Drug Administration Schedule

Share to Genomic Instability

Share to Loss of Heterozygosity

Share to Triple Negative Breast Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 25847936
DOI: 10.1200/JCO.2014.57.6660
PMCID: PMC4451173

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.PMID 25847936Read ↗

Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy.Semantic proximity Read ↗

Association between homologous recombination deficiency and outcomes with platinum and platinum-free chemotherapy in patients with triple-negative breast cancerSemantic proximity Read ↗

Biomarker Guided Chemotherapy and Immunotherapy Response in Asian Triple-Negative Breast Cancer: A Systematic ReviewSemantic proximity Read ↗

Efficacy of platinum-based chemotherapy in metastatic breast cancer and HRD biomarkers: utility of exome sequencingSemantic proximity Read ↗

TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker.Semantic proximity Read ↗

Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD‐L1 expression in cancer patientsSemantic proximity Read ↗

Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.Semantic proximity Read ↗

Platinum Salts in Patients with Breast Cancer: A Focus on Predictive FactorsSemantic proximity Read ↗

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.Semantic proximity Read ↗

Alterations in Homologous Recombination-Related Genes and Distinct Platinum Response in Metastatic Triple-Negative Breast Cancers: A Subgroup Analysis of the ProfiLER-01 TrialSemantic proximity Read ↗

Patient-Derived Xenograft-Guided Prediction of Chemotherapy Response in Triple-Negative Breast CancerSemantic proximity Read ↗

Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.